Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.45 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.41 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962557 | 0.95 | CRBN (0.57) | CRBNPOLBMAPTALDH1A1CSNK1A1 | |
| SCHEMBL1962950 | 0.91 | CRBN (0.55) | CRBNPOLBMAPTALDH1A1CSNK1A1 | |
| SCHEMBL1963376 | 0.90 | CRBN (0.53) | CRBNPOLBMAPTCSNK1A1IKZF1 | |
| SCHEMBL1963486 | 0.89 | CRBN (0.51) | CRBNCSNK1A1IKZF1MEN1KMT2A | |
| SCHEMBL1963522 | 0.89 | CRBN (0.51) | CRBNPOLBMAPTALDH1A1CSNK1A1 | |
| SCHEMBL1962928 | 0.87 | CRBN (0.52) | CRBNMAPTCSNK1A1IKZF2GSPT1 | |
| SCHEMBL1963723 | 0.87 | CRBN (0.52) | CRBNPOLBCSNK1A1IKZF1MEN1 | |
| SCHEMBL1961930 | 0.87 | CRBN (0.49) | CRBNPOLBCSNK1A1IKZF1MEN1 | |
| SCHEMBL1965760 | 0.86 | CRBN (0.55) | CRBNPOLBMAPTALDH1A1CSNK1A1 | |
| SCHEMBL1961959 | 0.86 | CRBN (0.55) | CRBNPOLBCSNK1A1IKZF1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | claimed |
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| EP-1919892-B1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8481568-B2 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SEPRACOR INC. | 2011-06-16 | — | — | US | disclosed |
| WO-2008134578-A2 | SYNTHESIS OF OPTICALLY ACTIVE RADIO-LABELED REVERSE TRANSCRIPTASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF (US) | 2008-11-06 | — | — | WO | disclosed |
| CN-101291924-A | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORP (US) | 2008-10-22 | — | — | CN | disclosed |
| EP-1919892-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027527-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885POLB 2035/4885MAPT 3296/4885 |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885POLB 2035/4885MAPT 3296/4885 |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SI, CYP3A5, CYP2D6 | CRBN 2589/4885POLB 2934/4885MAPT 553/4885 |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | SI, CYP3A5, CYP2D6 | CRBN 2589/4885POLB 2934/4885MAPT 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.